AstraZeneca's Koselugo Approved in EU for NF1
Ticker: AZN · Form: 6-K · Filed: Oct 28, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-approval, pediatric, rare-disease
TL;DR
EU approves AstraZeneca's Koselugo for kids with NF1 tumors.
AI Summary
AstraZeneca PLC announced on October 28, 2025, that Koselugo (selumeticinib) has received approval in the European Union. This approval is for the treatment of pediatric patients aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Why It Matters
This EU approval expands access to a crucial treatment for children with NF1 and plexiform neurofibromas, potentially improving their quality of life.
Risk Assessment
Risk Level: low — This is a routine regulatory filing announcing an approval, not a significant financial event.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant
- Koselugo (selumeticinib) (drug) — Approved medication
- European Union (location) — Approval jurisdiction
- October 28, 2025 (date) — Filing date
- neurofibromatosis type 1 (NF1) (medical_condition) — Indication for treatment
- pediatric patients (demographic) — Target patient group
FAQ
What is the specific indication for Koselugo's approval in the EU?
Koselugo is approved for the treatment of pediatric patients aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
When was this approval announced by AstraZeneca?
The announcement was made on October 28, 2025.
What is the active ingredient in Koselugo?
The active ingredient is selumeticinib.
Which regulatory body granted the approval in the EU?
The filing states approval in the European Union, implying a relevant EU regulatory authority.
What is the filing form type?
The filing form type is 6-K.
Filing Stats: 1,662 words · 7 min read · ~6 pages · Grade level 13.9 · Accepted 2025-10-28 08:02:56
Filing Documents
- a0174f.htm (6-K) — 39KB
- 0001654954-25-012262.txt ( ) — 40KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 28 October   2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary